false 0001123494 0001123494 2024-03-07 2024-03-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares



Washington, D.C. 20549










Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 7, 2024





(Exact name of registrant as specified in its charter)




Delaware 001-33957 04-3306140
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)


84 October Hill Road

Holliston, MA 01746

(Address of Principal Executive Offices) (Zip Code)


(508) 893-8999

(Registrant's telephone number, including area code)


(Former name or former address, if changed since last report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:    
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value HBIO The NASDAQ Stock Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 2.02. Results of Operations and Financial Condition.


On March 7, 2024, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the three and twelve months ended December 31, 2023, and the details of a related conference call to be held at 8:00 AM ET on March 7, 2024. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.


The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.



Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.


Exhibit Number  Description
99.1  Press Release issued by Harvard Bioscience, Inc. on March 7, 2024
104  Cover Page Interactive Data File (embedded within the XBRL document)






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: March 7, 2024 By: /s/ Jennifer Cote  
    Jennifer Cote  
    Chief Financial Officer  




EX-99.1 2 exh_991.htm EXHIBIT 99.1

Exhibit 99.1



Harvard Bioscience Announces Fourth Quarter 2023 Financial Results


·Q4 Revenues of $28.2 million
·Q4 Gross Margin of 58.0% (230 bps year-over-year improvement)
·Q4 operating income of $0.3 million, adjusted operating income of $3.3 million
·Strong operating cash flow enabled 2023 debt reduction of $10.5 million and a significant decrease in net leverage


HOLLISTON, Mass., March 7, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023.


Jim Green, Chairman and CEO said, “Our fourth quarter revenue was down a modest 1% compared to the prior year quarter in a challenging APAC marketplace. Revenue included a net reduction of approximately $0.9 million of remaining discontinued products from prior year. We saw significant gross margin expansion and continued our relentless focus on enhancing the product portfolio. At the same time, we introduced exciting new products which we expect to lead to future growth.”


Green continued, “We remain focused on solidifying our base business and expanding recurring revenue by introducing new products, services, and consumables. Our latest product introductions are penetrating exciting high growth adjacencies in bioproduction and advanced cell and organoid applications where we expect to see adoption in research, pharma, and biotech, in addition to high volume industrial applications.”


Financial Results Summary  Three Months Ended December 31,  Year Ended December 31,
(unaudited, $ in millions except per share data)  2023  2022  2023  2022
Revenues  $28.2   $28.4   $112.3   $113.3 
Gross margin   58.0%   55.7%   58.9%   53.7%
Operating income (loss) (GAAP)  $0.3   $(0.5)  $1.9   $(6.9)
Adjusted operating income  $3.3   $3.4   $13.1   $9.5 
Net loss (GAAP)  $(1.8)  $(1.7)  $(3.4)  $(9.5)
Diluted loss per share (GAAP)  $(0.04)  $(0.04)  $(0.08)  $(0.23)
Diluted adjusted earnings per share  $0.04   $0.04   $0.14   $0.12 
Adjusted EBITDA  $3.6   $3.7   $14.6   $10.8 
Adjusted EBITDA margin   13.0%   13.0%   13.0%   9.6%
Cash flow provided by operations  $4.3   $2.7   $14.0   $1.2 
Debt, including unamortized deferred financing costs            $36.6   $46.8 
Net debt (non-GAAP)            $32.8   $43.2 
Net leverage ratio (non-GAAP) (1)             2.3    4.0 


(1)Net leverage ratio is defined as our net debt divided by our trailing twelve-month adjusted EBITDA as defined in our credit agreement. For more information, please refer to the reconciliation of GAAP to non-GAAP financial measures included in the appendix to this press release.





Fourth Quarter 2023 Highlights


For the fourth quarter of fiscal 2023, the Company reported revenues of $28.2 million compared to $28.4 million in the fourth quarter of fiscal 2022 and included a net reduction of $0.9 million from discontinued products from the fourth quarter of 2022. Gross margin for the three months ended December 31, 2023 was 58.0% compared with 55.7% in the comparable quarter of the prior year.


Net loss for the fourth quarter of 2023 was $(1.8) million and included an unfavorable impact of a $(0.3) million unrealized loss on marketable securities. This compares to net loss of $(1.7) million in the fourth quarter of 2022. Adjusted EBITDA for the fourth quarter of 2023 was $3.6 million, compared to $3.7 million in the fourth quarter of the prior year.


Cash provided by operations for the fourth quarter of 2023 was $4.3 million compared to $2.7 million in the same period last year. Debt was reduced by $2.3 million during the quarter.


Year Ended December 31, 2023 Highlights


For the year ended December 31, 2023, revenues were $112.3 million, compared to $113.3 million in the same period a year ago. Revenues for the year include a net reduction of $5.0 million from discontinued products compared to 2022. Gross margin was 58.9% compared to 53.7% in the prior year. Gross margins in the prior year included the impact of a $1.5 million inventory charge related to the discontinued products.


Full year net loss was $(3.4) million, including an unfavorable $(0.6) million unrealized loss on marketable securities, compared to a net loss of $(9.5) million in the prior year, which included the aforementioned inventory charges. Adjusted EBITDA was $14.6 million, compared to $10.8 million in 2022.


Cash provided by operations in the year was $14.0 million compared to $1.2 million in the prior year. Debt was reduced by $10.5 million during the year.


2024 Guidance


For the full year 2024 we expect flat to modest revenue growth. We expect weakness in the first half versus a strong prior year comparison. We also expect strong second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in Chinese market conditions. In addition, we expect further gross margin expansion in the full year 2024 to approximately 60% compared to 59% in 2023 and adjusted EBITDA margin improving to the mid-teens compared to 13% in 2023.




This press release includes certain financial information presented on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, please see “Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.


Webcast and Conference Call Details


In conjunction with this announcement, Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will be posted to our Investor Relations website shortly before the webcast begins.


Analysts who want to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.


Participants who want to join the audio-only webcast should go to our events and presentations on the investor website here.


Use of Non-GAAP Financial Information


In this press release, we have included non-GAAP financial information, including one or more of adjusted operating income (loss), adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, diluted adjusted earnings (loss) per share, net debt and net leverage ratio. We believe that this non- GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, litigation settlement, restructuring and other costs, unrealized gain/loss on equity securities, income taxes, and. the tax impact of the reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company’s operating performance.


Non-GAAP historical financial statement information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure which is included as exhibits below in this press release.


With respect to non-GAAP forward-looking measures, we provide an outlook for adjusted EBITDA margin. Many of the items that we exclude from this forward-looking measure calculation are less capable of being controlled or reliably predicted by management. These items could cause the forward-looking measures presented in our outlook statements to vary materially from our GAAP results.


The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.




About Harvard Bioscience


Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.


For more information, please visit our website at www.harvardbioscience.com.


Forward-Looking Statements


This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, earnings, cash and debt position, growth and the introduction of new products, and the strength of the Company’s market position and business model. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.



Investor Inquiries:


Harvard Bioscience, Inc.

Investor Relations


(508) 893-3120










  Consolidated Statements of Operations  
  (unaudited, in thousands, except per share data)  
     Three Months Ended  Year Ended  
     December 31, 2023  December 31, 2022  December 31, 2023  December 31, 2022  
  Revenues  $28,153   $28,427   $112,250   $113,335   
  Cost of revenues   11,828    12,594    46,179    52,516   
  Gross profit   16,325    15,833    66,071    60,819   
  Operating expenses:                      
  Sales and marketing expenses   6,220    5,948    24,108    25,041   
  General and administrative expenses   5,286    5,863    22,780    24,493   
  Research and development expenses   3,150    2,849    11,764    12,329   
  Amortization of intangible assets   1,387    1,630    5,525    6,122   
  Litigation settlement   -    -    -    (233)  
  Total operating expenses   16,043    16,290    64,177    67,752   
  Operating income (loss)   282    (457)   1,894    (6,933)  
  Other (expense) income:                      
  Interest expense   (794)   (900)   (3,591)   (2,548)  
  Unrealized loss on equity securities   (259)   -    (632)   -   
  Other (expense) income, net   (332)   465    (227)   302   
  Total other expense   (1,385)   (435)   (4,450)   (2,246)  
  Loss before income taxes   (1,103)   (892)   (2,556)   (9,179)  
  Income tax expense   715    774    859    337   
  Net loss  $(1,818)  $(1,666)  $(3,415)  $(9,516)  
  Loss per common share:                      
  Basic and diluted  $(0.04)  $(0.04)  $(0.08)  $(0.23)  
  Weighted-average common shares:                      
  Basic and diluted   42,710    42,102    42,420    41,413   





  Condensed Consolidated Balance Sheets  
  (unaudited, in thousands)  
     December 31,  
     2023  2022  
  Cash and cash equivalents  $4,283   $4,508   
  Accounts receivable, net   16,099    16,705   
  Inventories   24,716    26,439   
  Other current assets   3,940    3,472   
  Total current assets   49,038    51,124   
  Property, plant and equipment   3,981    3,366   
  Goodwill and other intangibles   73,101    77,274   
  Other long-term assets   11,246    13,596   
  Total assets  $137,366   $145,360   
  Liabilities and Stockholders' Equity            
  Current portion, long-term debt  $5,859   $3,811   
  Other current liabilities   20,683    19,438   
  Total current liabilities   26,542    23,249   
  Long-term debt, net   30,704    43,013   
  Other long-term liabilities   7,046    6,878   
  Stockholders’ equity   73,074    72,220   
  Total liabilities and stockholders’ equity  $137,366   $145,360   






  Condensed Consolidated Statements of Cash Flows  
  (unaudited, in thousands)  
     Three Months Ended  Year Ended  
     December 31, 2023  December 31, 2022  December 31, 2023  December 31, 2022  
  Cash flows from operating activities:                      
  Net loss  $(1,818)  $(1,666)  $(3,415)  $(9,516)  
  Adjustments to operating cash flows   3,732    2,787    12,843    7,952   
  Changes in operating assets and liabilities   2,389    1,558    4,600    2,716   
  Net cash provided by operating activities   4,303    2,679    14,028    1,152   
  Cash flows from investing activities:                      
  Additions to property, plant and equipment   (830)   (235)   (1,788)   (1,590)  
  Acquisition of intangible assets   (231)   -    (523)   -   
  Proceeds from sale of product line   -    -    512    -   
  Net cash used in investing activities   (1,061)   (235)   (1,799)   (1,590)  
  Cash flows from financing activities:                      
  Borrowing from revolving line of credit   1,000    -    4,500    7,800   
  Repayment of revolving line of credit   (2,500)   (1,750)   (10,950)   (6,400)  
  Repayment of term debt   (750)   (750)   (4,091)   (3,186)  
  Proceeds from exercise of employee stock options and purchases   206    231    930    577   
  Taxes paid related to net share settlement of equity awards   (2,072)   (461)   (2,523)   (1,628)  
  Net cash used in financing activities   (4,116)   (2,730)   (12,134)   (2,837)  
  Effect of exchange rate changes on cash and cash equivalents   (183)   (350)   (320)   (38)  
  Decrease in cash and cash equivalents   (1,057)   (636)   (225)   (3,313)  
  Cash and cash equivalents at the beginning of period   5,340    5,144    4,508    7,821   
  Cash and cash equivalents at the end of period  $4,283   $4,508   $4,283   $4,508   






  Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)  
  (in thousands, except per share data)  
     Three Months Ended  Year Ended  
     December 31, 2023  December 31, 2022  December 31, 2023  December 31, 2022  
  GAAP operating income (loss)  $282   $(457)  $1,894   $(6,933)  
  Stock-based compensation   1,382    1,010    5,000    4,411   
  Acquired asset amortization   1,394    1,648    5,561    6,236   
  Restructuring & other   207    1,168    656    6,016   
  Litigation settlement   -    -    -    (233)  
  Adjusted operating income  $3,265   $3,369   $13,111   $9,497   
  Operating margin   1.0%   -1.6%   1.7%   -6.1%  
  Adjusted operating margin   11.6%   11.9%   11.7%   8.4%  
  GAAP net loss  $(1,818)  $(1,666)  $(3,415)  $(9,516)  
  Stock-based compensation   1,382    1,010    5,000    4,411   
  Acquired asset amortization   1,394    1,648    5,561    6,236   
  Restructuring & other   207    1,068    253    5,836   
  Litigation settlement   -    -    -    (233)  
  Unrealized loss on equity securities   258    -    632    -   
  Income taxes   315    (281)   (1,604)   (1,689)  
  Adjusted net income   1,738    1,779    6,427    5,045   
  Depreciation   386    314    1,440    1,338   
  Interest and other expense, net   1,126    536    4,221    2,426   
  Adjusted income taxes (1)   400    1,054    2,463    2,026   
  Adjusted EBITDA  $3,650   $3,683   $14,551   $10,835   
  Adjusted EBITDA margin   13.0%   13.0%   13.0%   9.6%  
  Diluted loss per share (GAAP)  $(0.04)  $(0.04)  $(0.08)  $(0.23)  
  Diluted adjusted earnings per share  $0.04   $0.04   $0.14   $0.12   
  Weighted-average common shares:                      
  Diluted GAAP   42,710    42,102    42,420    41,413   
  Diluted Adjusted   44,819    42,740    44,361    42,682   
                December 31, 2023    December 31, 2022   
  Debt, including unamortized deferred financing costs            $36,563   $46,824   
  Unamortized deferred financing costs             560    840   
  Cash and cash equivalents             (4,283)   (4,508)  
  Net debt            $32,840   $43,156   
  Net leverage ratio (2)             2.3    4.0   
  (1) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise.  
  (2) Net leverage ratio is defined herein as net debt divided by our trailing twelve months adjusted EBITDA as defined in our credit agreement and as shown above.  


GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg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end EX-101.SCH 4 hbio-20240307.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 hbio-20240307_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 hbio-20240307_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Mar. 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 07, 2024
Entity File Number 001-33957
Entity Registrant Name HARVARD BIOSCIENCE, INC.
Entity Central Index Key 0001123494
Entity Tax Identification Number 04-3306140
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 84 October Hill Road
Entity Address, City or Town Holliston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01746
City Area Code (508)
Local Phone Number 893-8999
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol HBIO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_030624.htm hbio-20240307.xsd hbio-20240307_lab.xml hbio-20240307_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_030624.htm": { "nsprefix": "HBIO", "nsuri": "http://globenewswire.com/20240307", "dts": { "inline": { "local": [ "f8k_030624.htm" ] }, "schema": { "local": [ "hbio-20240307.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "hbio-20240307_lab.xml" ] }, "presentationLink": { "local": [ "hbio-20240307_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_030624.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_030624.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001171843-24-001222-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-24-001222-xbrl.zip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end XML 17 f8k_030624_htm.xml IDEA: XBRL DOCUMENT 0001123494 2024-03-07 2024-03-07 iso4217:USD shares iso4217:USD shares false 0001123494 8-K 2024-03-07 HARVARD BIOSCIENCE, INC. DE 001-33957 04-3306140 84 October Hill Road Holliston MA 01746 (508) 893-8999 false false false false Common Stock, $0.01 par value HBIO NASDAQ false